JMP Securities Boosts Benitec Biopharma (NASDAQ:BNTC) Price Target to $18.00

Benitec Biopharma (NASDAQ:BNTC) had its price objective boosted by JMP Securities from $16.00 to $18.00 in a report issued on Monday, Benzinga reports. JMP Securities currently has a market outperform rating on the biotechnology company’s stock.

BNTC has been the topic of a number of other reports. Guggenheim assumed coverage on shares of Benitec Biopharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $17.00 price target on the stock. Leerink Partners initiated coverage on shares of Benitec Biopharma in a report on Monday, July 22nd. They issued an “outperform” rating and a $13.00 target price on the stock. Finally, Leerink Partnrs raised shares of Benitec Biopharma to a “strong-buy” rating in a report on Monday, July 22nd. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $22.60.

Benitec Biopharma Stock Performance

NASDAQ:BNTC opened at $9.81 on Monday. Benitec Biopharma has a 1-year low of $2.69 and a 1-year high of $12.89. The firm has a market capitalization of $91.90 million, a price-to-earnings ratio of -5.14 and a beta of 0.90. The business’s 50-day moving average price is $9.13 and its two-hundred day moving average price is $8.33.

Institutional Investors Weigh In On Benitec Biopharma

A number of hedge funds and other institutional investors have recently made changes to their positions in BNTC. GAMMA Investing LLC lifted its holdings in shares of Benitec Biopharma by 53.0% in the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 1,884 shares in the last quarter. Simplify Asset Management Inc. bought a new stake in Benitec Biopharma in the 2nd quarter valued at approximately $358,000. Janus Henderson Group PLC boosted its position in Benitec Biopharma by 35.5% during the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock worth $1,266,000 after acquiring an additional 64,092 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new position in shares of Benitec Biopharma during the 2nd quarter worth approximately $5,881,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.